As shown in Figure 3, the interplay of a pro-senescence therapy, e.g., MRTF or MYOF siRNA application, and a senolytic therapy, e.g. with ABT-263, represents a promising strategy for HCC treatment by positively effecting the bad outcome of an accumulation of harmful SASP due to senescence induction and turning it into a positive outcome for HCC. Here, MYOF is linked to hepatocellular carcinoma.